EP3984597A4 - Development of therapy for improving myocardial contraction and method for inhibiting cardiomyocyte death - Google Patents

Development of therapy for improving myocardial contraction and method for inhibiting cardiomyocyte death Download PDF

Info

Publication number
EP3984597A4
EP3984597A4 EP20840275.0A EP20840275A EP3984597A4 EP 3984597 A4 EP3984597 A4 EP 3984597A4 EP 20840275 A EP20840275 A EP 20840275A EP 3984597 A4 EP3984597 A4 EP 3984597A4
Authority
EP
European Patent Office
Prior art keywords
therapy
development
myocardial contraction
improving myocardial
cardiomyocyte death
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20840275.0A
Other languages
German (de)
French (fr)
Other versions
EP3984597A1 (en
Inventor
Hiroyuki Tsutsui
Tomomi Ide
Kisho Ohtani
Shoji MATSUSHIMA
Masataka Ikeda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyushu University NUC
Original Assignee
Kyushu University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyushu University NUC filed Critical Kyushu University NUC
Publication of EP3984597A1 publication Critical patent/EP3984597A1/en
Publication of EP3984597A4 publication Critical patent/EP3984597A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
EP20840275.0A 2019-07-12 2020-07-10 Development of therapy for improving myocardial contraction and method for inhibiting cardiomyocyte death Pending EP3984597A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019130571 2019-07-12
PCT/JP2020/027115 WO2021010344A1 (en) 2019-07-12 2020-07-10 Development of therapy for improving myocardial contraction and method for inhibiting cardiomyocyte death

Publications (2)

Publication Number Publication Date
EP3984597A1 EP3984597A1 (en) 2022-04-20
EP3984597A4 true EP3984597A4 (en) 2023-07-12

Family

ID=74210859

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20840275.0A Pending EP3984597A4 (en) 2019-07-12 2020-07-10 Development of therapy for improving myocardial contraction and method for inhibiting cardiomyocyte death

Country Status (6)

Country Link
US (1) US20220273709A1 (en)
EP (1) EP3984597A4 (en)
JP (1) JPWO2021010344A1 (en)
CN (1) CN114096260A (en)
CA (1) CA3148229A1 (en)
WO (1) WO2021010344A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015129791A1 (en) * 2014-02-26 2015-09-03 国立大学法人北海道大学 Pharmaceutical containing dendritic cells, and method for producing same
WO2020179104A1 (en) * 2019-03-04 2020-09-10 国立大学法人北海道大学 PHARMACEUTICAL COMPOSITION COMPRISING α-GALACTOSYLCERAMIDE AND/OR DENDRITIC CELLS PULSED WITH α-GALACTOSYLCERAMIDE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0211968A (en) 2001-08-16 2004-09-28 Daiichi Suntory Pharma Co Ltd Glycolipid useful in the treatment of autoimmune diseases and its medicine
CA2517295C (en) * 2003-02-27 2016-01-12 Northwest Biotherapeutics, Inc. Generation of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines
CN102552235B (en) * 2010-12-16 2014-07-09 复旦大学 Application of eonurine-cysteine conjugate in preparing medicine used for treating ischaemic cardiomyopathy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015129791A1 (en) * 2014-02-26 2015-09-03 国立大学法人北海道大学 Pharmaceutical containing dendritic cells, and method for producing same
WO2020179104A1 (en) * 2019-03-04 2020-09-10 国立大学法人北海道大学 PHARMACEUTICAL COMPOSITION COMPRISING α-GALACTOSYLCERAMIDE AND/OR DENDRITIC CELLS PULSED WITH α-GALACTOSYLCERAMIDE

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EIICHI ISHIKAWA ET AL: "Dendritic cell maturation by CD11c- T cells and V[alpha]24+ natural killer T-cell activation by [alpha]-Galactosylceramide", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 117, no. 2, 17 May 2005 (2005-05-17), pages 265 - 273, XP071282562, ISSN: 0020-7136, DOI: 10.1002/IJC.21197 *
See also references of WO2021010344A1 *

Also Published As

Publication number Publication date
US20220273709A1 (en) 2022-09-01
EP3984597A1 (en) 2022-04-20
CN114096260A (en) 2022-02-25
JPWO2021010344A1 (en) 2021-01-21
WO2021010344A1 (en) 2021-01-21
CA3148229A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
EP3856176A4 (en) Inhibitors of vap-1
EP3782618A4 (en) Method for preventing or treating side effects of cancer therapy
EP3873478A4 (en) Method of enhancing immune-based therapy
EP4017489A4 (en) Method of treating kras-associated cancers
EP3919197A4 (en) Method for identifying variation factor portion of springback amount
EP3838901A4 (en) Compound for treatment of rabies and method for treatment of rabies
EP4031577A4 (en) A method of engineering natural killer-cells to target bcma-positive tumors
EP4067817A4 (en) System and method for spatial positioning of magnetometers
EP3908650A4 (en) Methods of treating cancer
EP3891184A4 (en) Method of treating neutrophilic conditions
EP3820563A4 (en) Method of treating voiding dysfunction
EP3938364A4 (en) Compounds for and methods of treating diseases
EP3958892A4 (en) Methods of treating liver disease
EP4017490A4 (en) Compounds and methods for treating oxalate-related diseases
EP3984597A4 (en) Development of therapy for improving myocardial contraction and method for inhibiting cardiomyocyte death
EP3946419A4 (en) Methods of treating cancer with chk1 inhibitors
EP3952858A4 (en) Method of treating tumours
EP3893882A4 (en) Cxcr7 inhibitors for the treatment of cancer
EP4037682A4 (en) Methods of treating pompe disease
IL289811A (en) Method of treating cancer
EP4072561A4 (en) Methods of treating cancer
EP3914235A4 (en) Methods of treating addiction
EP4058140A4 (en) Methods of treating ascites
EP3937922A4 (en) Methods of treating organic acidemias
EP4008723A4 (en) Cell death inhibitor and cell death inhibition method

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61P0009000000

Ipc: A61K0035150000

A4 Supplementary search report drawn up and despatched

Effective date: 20230614

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/704 20060101ALI20230607BHEP

Ipc: A61P 43/00 20060101ALI20230607BHEP

Ipc: A61P 9/10 20060101ALI20230607BHEP

Ipc: A61P 9/04 20060101ALI20230607BHEP

Ipc: A61P 9/00 20060101ALI20230607BHEP

Ipc: A61K 35/15 20150101AFI20230607BHEP